Source: International Congress 2019 – Airway infection in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Titova (Trondheim , Norway), L. Løfblad (Trondheim , Norway), A. Åsberg (Trondheim , Norway), A. Henriksen (Trondheim , Norway). Calprotectin as a biomarker of pneumonia in patients hospitalized with AECOPD. 2895

Member's Comments

No comment yet.

Related content which might interest you: How can I differentiate community-acquired pneumonia (CAP)+COPD patients from acute exacerbation of COPD (AECOPD) patients? Source: International Congress 2015 – Differentiating COPD exacerbations from pneumonia in COPD patients Year: 2015 Lactate is an independent marker of severity in hospitalised patients with community-acquired pneumonia Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Validity of the diagnosis of pneumonia in hospitalised patients with COPD Source: ERJ Open Res, 5 (2) 00031-2019; 10.1183/23120541.00031-2019 Year: 2019 Heliox-therapy of patients with execerbation of COPD and community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 106s Year: 2006 Procalcitonin as a predictor of pneumonia in patients hospitalized with acute exacerbation of COPD: a prospective observational study Source: International Congress 2017 – COPD biomarkers Year: 2017 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 Comparison of inflammatory response biomarkers to predict complications in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD Source: Eur Respir J 2015; 45: 76-86 Year: 2015 Diagnostic and prognostic value of C-reactive protein in community-acquired pneumonia hospitalized patients Source: Eur Respir J 2004; 24: Suppl. 48, 188s Year: 2004 Inflammatory biomarkers in predicting ICU admission of severe community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Pulmonary infections and sepsis Year: 2011 Serum periostin in patients hospitalized for COPD exacerbations Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015 Serum procalcitonin (PCT-Q) as a diagnostic tool for bacterial lower respiratory tract infection among COPD patients with acute exacerbation Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 CRP and ESR as discharged criteria of patients admitted with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 374s Year: 2006 Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation Source: International Congress 2016 – Inflammatory biomarkers in airway diseases Year: 2016 Polypharmacy in patients hospitalised for acute exacerbation of COPD Source: Eur Respir J 2014; 44: 791-794 Year: 2014 Cardiac troponin increases in COPD patients hospitalised for pneumonias as well as exacerbations Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Neutrophil CD 64 expression as a diagnostic marker of pneumonia in patients with acute COPD exacerbation Source: International Congress 2014 – Markers Year: 2014 Procalcitonin use in acute exacerbations of COPD Source: Annual Congress 2011 - COPD exacerbation Year: 2011 YKL-40 and CCL18 predict mortality in patients hospitalised with community-acquired pneumonia; an observational analysis Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016